eligibility_summary
Adults 18–74 with relapsed/refractory hematologic malignancies expressing validated targets (e.g., CD19, CD22, CD20, CD7, CD5, CD2, CD79b, BCMA, GPRC5D, CD38, CD33, CD123, CD133, CLL1, EBV, CMV), including refractory/newly diagnosed progression on chemo or relapse after chemo, HSCT, or CAR‑T, not curable by standard care. Exclude: life expectancy <12 wks, severe GVHD, early post‑HSCT without donor, organ dysfunction, active infection (HBV/HCV/HIV), poor follow‑up, no consent, target‑antigen mutations, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Personalized chimeric antigen receptor T‑cell (CAR‑T) therapy (gene‑modified cell therapy), using lentiviral transduction of autologous or allogeneic T cells, IV infusion at 2×10^6–1×10^7 CAR‑T/kg with dose escalation to define MTD. Mechanism: Engineered CARs bind predefined tumor surface antigens in an MHC‑independent manner, triggering T‑cell activation and cytotoxicity (perforin/granzyme release) and cytokine‑mediated tumor clearance. Targets/cells/pathways: Antigens across hematologic malignancies—B‑cell (CD19, CD20, CD22, CD79b), plasma cell/myeloma (BCMA, GPRC5D, CD38), T‑cell (CD7, CD5, CD2), myeloid (CD33, CD123, CD133, CLL‑1), and viral (EBV GP350, LMP1, CMV gB). Primary targets are malignant B cells, plasma cells, T cells, and myeloid blasts via CAR signaling pathways.